SCHEDULE: Deep Track Capital Reports 3.64% Stake in MBX Biosciences

Deep Track Capital, LP, along with affiliated entities, has reported beneficial ownership of 3.64% of MBX Biosciences, Inc. common stock as of June 30, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, indicating their beneficial ownership of MBX Biosciences, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 1,732,569 shares of common stock.
• This ownership represents 3.64% of the class of securities outstanding.
• The filing confirms that David Kroin may be considered a control person of Deep Track Capital, LP.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new strategic or financial information.

Positives

• The filing clearly states that the securities were not acquired or held for the purpose of changing or influencing control of MBX Biosciences, Inc., which can be seen as a positive signal of passive investment.
• The reporting persons have shared voting and dispositive power over the 1,732,569 shares, indicating a coordinated approach to their investment.

Negatives

• The filing does not provide any new financial performance data or strategic updates for MBX Biosciences, Inc., limiting insights into the company's operational health.
• The ownership stake of 3.64% is significant but does not grant controlling interest, potentially limiting the reporting persons' ability to influence company direction.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.
• Potential future changes in beneficial ownership by Deep Track Capital, LP or other entities could impact MBX Biosciences, Inc.'s stock price and corporate control dynamics.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance regarding MBX Biosciences, Inc.'s future performance.

Management Comments

• David Kroin, Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, certified that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
• David Kroin, Director for Deep Track Biotechnology Master Fund, Ltd., provided a similar certification.
• David Kroin certified that the information set forth in the statement is true, complete and correct.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Deep Track Capital's interest in MBX Biosciences, Inc., a biotechnology company, aligning with typical investment patterns in the sector.

Comparison to Industry Standards

• The filing does not provide performance metrics for MBX Biosciences, Inc. that can be compared to industry standards.
• The ownership percentage of 3.64% is a common threshold for institutional investors to report their holdings, but without further context on MBX Biosciences' specific market or stage of development, direct comparison to other companies' investor profiles is difficult.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest in MBX Biosciences, Inc., potentially influencing stock price. However, the passive nature of the filing suggests no immediate intent to influence corporate strategy.
• Management: The reporting persons' stake is noted, but the certification of no intent to influence control means management's current operational strategies are unlikely to be immediately impacted.
• Creditors: No direct impact is indicated as the filing does not concern debt or financial distress.

Next Steps

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin will be responsible for the timely filing of any subsequent amendments to this Schedule 13G.
• Further filings may be required if the reporting persons' beneficial ownership changes significantly.

Key Dates

Keywords

MBX Biosciences, Deep Track Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Cayman Islands, Delaware